Literature DB >> 3086279

In-vitro activity of pefloxacin compared to other antibiotics.

E Yourassowsky, M P Van der Linden, F Crokaert, Y Glupczynski.   

Abstract

Pefloxacin is a new quinolone carboxylic acid with a broad spectrum of antibacterial activity. A comparison was made of the in-vitro activity of pefloxacin and that of nine other antibiotics (ampicillin, ticarcillin, piperacillin, cefazolin, cefotaxime, ceftazidime, gentamicin, amikacin and norfloxacin). The MIC90 of pefloxacin against 500 strains of Enterobacteriaceae ranged from 0.25 mg/l (Escherichia coli, indole + Proteus spp., Enterobacter cloacae, Salmonella spp. and Shigella spp.) to 1 mg/l (Klebsiella pneumoniae). Pefloxacin inhibited 90% of 52 strains of Pseudomonas aeruginosa at 2.5 mg/l (range 0.25 mg/l-4 mg/l). The MIC90 of pefloxacin against 100 Staphylococcus aureus strains (78 oxacillin resistant strains) was 0.4 mg/l (range 0.12-0.5 mg/l). It was markedly less active against Streptococcus faecalis and Str. pneumoniae (37 strains of each species) the MIC90 being 4 mg/l against both species. Overall, pefloxacin was at least as active as the third-generation cephalosporins against Enterobacteriaceae and was more active than any other antibiotic tested against P. aeruginosa, S. epidermidis, and S. aureus. Against E. coli, pefloxacin had a more rapid anti-bacterial activity than piperacillin. A paradoxical effect was observed with pefloxacin. An optimal killing rate was observed at concentrations of pefloxacin compatible with those one can expect in blood of patients treated with this drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086279     DOI: 10.1093/jac/17.suppl_b.19

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Clinical experience with pefloxacin in the therapy of typhoid fever.

Authors:  P Cristiano; G Morelli; V Briante; M R Iovene; F Simioli; P Altucci
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

2.  Intraperitoneal penetration of pefloxacin.

Authors:  J M Webberly; I Donovan; R Wise; J Ashby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

3.  Pharmacokinetics and tissue penetration of orally administered pefloxacin.

Authors:  J M Webberley; J M Andrews; J P Ashby; A McLeod; R Wise
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

4.  Pefloxacin versus chloramphenicol in the therapy of typhoid fever.

Authors:  P Cristiano; L Imparato; C Carpinelli; F Lauria; M R Iovene; M F Corrado; P Maio; C Imperatore
Journal:  Infection       Date:  1995 Mar-Apr       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.